Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KBA651
- Development stage
- Preclinical
- Lead developer
- K2B Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KBA651 is an engineered SIRPα-based antibody-drug conjugate (ADC) developed by K2B Therapeutics for the treatment of solid tumors, including metastatic colorectal cancer (mCRC), ovarian cancer (OC), and small cell lung cancer (SCLC). The molecule consists of an engineered Signal Regulatory Protein Alpha (SIRPα) domain conjugated to the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE). KBA651 targets the CD47/SIRPα axis by binding to CD47, a "don't eat me" signal frequently overexpressed on tumor cells. This binding allows for the selective delivery of the MMAE payload into the tumor cells, leading to cell death. By targeting CD47, KBA651 may also block the inhibitory signal to macrophages, potentially enhancing the anti-tumor immune response. The program is currently in the preclinical stage of development.
- Other names
- eSIRPα-MMAE
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on KBA651.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KBA651.